經皮冠狀動脈介入治療後新型口服抗凝血劑（NOAC）：網絡 ... | 合法醫療器材資訊網

2019年12月20日—他們需要服用血液稀釋劑以預防中風，並需要使用抗血小板藥物來預防支架中的血栓。然而，這種組合增加了潛在危及生命的出血風險，因此，最佳 ...

Coronary artery disease (CAD) is the leading cause of death worldwide (Benjamin 2018[1]; Finegold 2013[2]). According to the World Health Organization (WHO), CAD is responsible for about 15% of all deaths globally (WHO 2015[3]). It remains one of the worlds largest health problems, despite dramatic medical advances over the last few decades.

CAD is usually caused by atherosclerosis, in which fatty deposits accumulate on the walls of the coronary arteries. In general, CAD is classified into chronic coronary syndromes and acute coronary syndrome, the latter of which has three forms: unstable angina, non‐ST‐elevation myocardial infarction, and ST‐elevation myocardial infarction (Ibanez 2018[4]; Knuuti 2019[5]; Roffi 2016[6])).

Percutaneous coronary intervention (PCI) is the most common procedure used in the invasive treatment of people with CA...